WINT vs. CLDI, TCBP, CHRO, FRTX, TTNP, BCDA, CELZ, ALBT, SRNE, and PALI
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Calidi Biotherapeutics (CLDI), TC Biopharm (TCBP), Chromocell Therapeutics (CHRO), Fresh Tracks Therapeutics (FRTX), Titan Pharmaceuticals (TTNP), BioCardia (BCDA), Creative Medical Technology (CELZ), Avalon GloboCare (ALBT), Sorrento Therapeutics (SRNE), and Palisade Bio (PALI). These companies are all part of the "biological products, except diagnostic" industry.
Windtree Therapeutics (NASDAQ:WINT) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.
Calidi Biotherapeutics has a consensus target price of $16.67, suggesting a potential upside of 954.85%. Given Calidi Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Calidi Biotherapeutics is more favorable than Windtree Therapeutics.
29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 0.5% of Windtree Therapeutics shares are owned by insiders. Comparatively, 34.5% of Calidi Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Windtree Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.
Windtree Therapeutics received 3 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users.
In the previous week, Windtree Therapeutics had 11 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 11 mentions for Windtree Therapeutics and 0 mentions for Calidi Biotherapeutics. Windtree Therapeutics' average media sentiment score of 0.49 beat Calidi Biotherapeutics' score of -1.02 indicating that Windtree Therapeutics is being referred to more favorably in the media.
Calidi Biotherapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.
Windtree Therapeutics has higher earnings, but lower revenue than Calidi Biotherapeutics.
Summary
Calidi Biotherapeutics beats Windtree Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Windtree Therapeutics Competitors List
Related Companies and Tools
